GlassScriptPhysician profile
John T Palma
NPI 1730690546
$13,606.15
in general payments reported to CMS, 2019-2025
26 companies · $3,422 in 2025
The $3,422 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,242 · 2022: $2,043 · 2023: $2,774 · 2024: $3,125 · 2025: $3,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,272 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,271.97 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,853.42 | 2021-2025 | |
| Corium, LLC | $1,860.77 | 2022-2025 | Azstarys, Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $1,322.14 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,301.45 | 2022-2025 | Caplyta |
| Lundbeck LLC | $1,179.95 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $967.21 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $638.70 | 2022-2025 | Aristada, Lybalvi |
| Bausch Health US, LLC | $485.68 | 2021-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $408.50 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $390.71 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $281.82 | 2021-2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $264.65 | 2023-2024 | Jornay Pm |
| Eisai INC. | $224.64 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $222.41 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $221.58 | 2022-2024 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $196.41 | 2021-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $164.79 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $158.50 | 2021-2023 | Belsomra |
| Vertical Pharmaceuticals, LLC | $156.87 | 2024-2025 | Relexxii |
| Jazz Pharmaceuticals INC. | $93.50 | 2021-2022 | |
| Tris Pharma INC | $91.36 | 2024-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $45.52 | 2025 | Spravato |
| Adlon Therapeutics L.P. | $24.26 | 2021 | |
| Neurocrine Biosciences, INC. | $21.45 | 2025 | |
| Azurity Pharmaceuticals, INC. | $15.37 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $14.49 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Palma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.